Stock A214390 KYONGBO PHARMACEUTICAL CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Kyongbo Pharmaceutical Co., Ltd

Equities

A214390

KR7214390007

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 19:00:00 2024-03-26 EDT 		5-day change 1st Jan Change
7,440 KRW -2.75% Intraday chart for Kyongbo Pharmaceutical Co., Ltd -.--% -11.32%
2023 Pharosgen Co., Ltd. announced that it has received KRW 1.999997692 billion in funding from Kyongbo Pharmaceutical Co., Ltd CI
2023 Kyongbo Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 245,045 197,471 390,877 256,999 239,069 200,579
Enterprise Value (EV) 1 282,631 247,124 433,160 309,295 296,362 271,168
P/E ratio 18.7 x 37.4 x 41.6 x -34.3 x 392 x 67.4 x
Yield - - - - - -
Capitalization / Revenue 1.22 x 1.03 x 1.82 x 1.51 x 1.22 x 0.93 x
EV / Revenue 1.4 x 1.29 x 2.01 x 1.81 x 1.51 x 1.25 x
EV / EBITDA 9.81 x 13.2 x 20.4 x 50.4 x 22.2 x 15.7 x
EV / FCF -25.9 x 187 x 59.1 x 342 x -58.6 x -42.7 x
FCF Yield -3.86% 0.54% 1.69% 0.29% -1.71% -2.34%
Price to Book 1.64 x 1.32 x 2.5 x 1.76 x 1.66 x 1.39 x
Nbr of stocks (in thousands) 23,907 23,907 23,907 23,907 23,907 23,907
Reference price 2 10,250 8,260 16,350 10,750 10,000 8,390
Announcement Date 3/1/19 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 201,344 191,706 215,285 170,660 196,265 216,357
EBITDA 1 28,824 18,783 21,249 6,132 13,328 17,244
EBIT 1 17,267 6,194 8,661 -6,625 1,393 5,545
Operating Margin 8.58% 3.23% 4.02% -3.88% 0.71% 2.56%
Earnings before Tax (EBT) 1 17,644 6,982 14,031 -9,933 -614.8 2,172
Net income 1 13,116 5,285 9,404 -7,495 610.6 2,974
Net margin 6.51% 2.76% 4.37% -4.39% 0.31% 1.37%
EPS 2 548.6 221.1 393.4 -313.5 25.54 124.4
Free Cash Flow 1 -10,923 1,324 7,333 904.9 -5,058 -6,351
FCF margin -5.43% 0.69% 3.41% 0.53% -2.58% -2.94%
FCF Conversion (EBITDA) - 7.05% 34.51% 14.76% - -
FCF Conversion (Net income) - 25.06% 77.97% - - -
Dividend per Share - - - - - -
Announcement Date 3/1/19 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 37,586 49,653 42,283 52,296 57,294 70,589
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.304 x 2.644 x 1.99 x 8.529 x 4.299 x 4.094 x
Free Cash Flow 1 -10,923 1,324 7,333 905 -5,058 -6,351
ROE (net income / shareholders' equity) 9.03% 3.55% 6.16% -4.97% 0.42% 2.06%
ROA (Net income/ Total Assets) 5.06% 1.69% 2.2% -1.69% 0.36% 1.37%
Assets 1 259,180 313,627 426,564 443,712 167,515 217,522
Book Value Per Share 2 6,233 6,239 6,528 6,095 6,011 6,039
Cash Flow per Share 2 209.0 283.0 478.0 179.0 266.0 187.0
Capex 1 7,623 20,649 12,056 17,506 12,874 9,693
Capex / Sales 3.79% 10.77% 5.6% 10.26% 6.56% 4.48%
Announcement Date 3/1/19 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
KYONGBO PHARMACEUTICAL CO., LTD Stock Kyongbo Pharmaceutical Co., Ltd
-11.32% 131M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.26% 705B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.82% 583B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.76% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.03% 332B
ABBVIE INC. Stock AbbVie Inc.
+4.93% 291B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.64% 238B
ROCHE HOLDING AG Stock Roche Holding AG
-4.13% 210B
NOVARTIS AG Stock Novartis AG
+10.63% 209B
AMGEN INC. Stock Amgen Inc.
+8.80% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A214390 Stock
  4. Financials Kyongbo Pharmaceutical Co., Ltd
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW